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ABSTRACT
Familial Papillary Thyroid Carcinoma (PTC) has been described as a hereditary 
predisposition cancer syndrome associated with mutations in candidate genes including 
HABP2. Two of 20 probands from families with history of PTC and breast carcinoma (BC) 
were evaluated by whole exome sequencing (WES) revealing HABP2 p.G534E. Sanger 
sequencing was used to confirm the involvement of this variant in three families (F1: 7 
relatives; F2: 3 and F3: 3). The proband and his sister (with no malignant tumor so far) from 
F1 were homozygous for the variant whereas one relative with PTC from F2 was negative 
for the variant. Although the proband of the F3 with PTC was HABP2 wild type, three 
relatives presented the variant. Five of 170 healthy Brazilian individuals with no family 
history of BC or PTC and three of 50 sporadic PTC presented the p.G534E. These findings 
suggested no association of this variant with our familial PTC cases. Genes potentially 
associated with deregulation of the extracellular matrix organization pathway (CTSB, TNXB, 
COL4A3, COL16A1, COL24A1, COL5A2, NID1, LOXL2, MMP11, TRIM24 and MUSK) and DNA 
repair function (NBN and MSH2) were detected by WES, suggesting that other cancer-
associated genes have pathogenic effects in the risk of familial PTC development.
INTRODUCTION
Thyroid Carcinoma (TC) is a common endocrine 
neoplasia corresponding to 1% of all cancers worldwide 
[1, 2]. Non-Medullary Thyroid Carcinoma (NMTC), 
which includes Papillary Thyroid Carcinoma (PTC) and 
Follicular Thyroid Carcinoma (FTC), is the most common 
tumor involving the thyroid gland, the former being 
responsible for 80-95% of all cases [3, 4].
Family history of NMTCs has been associated with 
well known Hereditary Cancer Predisposition Syndromes 
(HCPS) including Cowden, Familial Adenomatosis Polyposis/
Gardner, Carney Complex type 1, Werner and DICER1 
syndromes, which were associated with mutations in PTEN, 
APC, PRKAR1A, WRN and DICER1 genes, respectively [5, 
6]. Although TC has been reported in families with Lynch 
and Li-Fraumeni syndromes, its inclusion in the spectrum of 
tumors of these disorders remains to be clarified [7-11].
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The predominance of PTC in families having first 
or second degree relatives affected by the disease has been 
described as a particular clinical entity suggestive of a 
heritable component. Based on this premise, new candidate 
genes have been reported as associated with familial PTC 
including HABP2, SRGAP1, PARP4 and SRRM2 [12-15].
Gara et al. (2015) reported a novel non-synonymous 
p.G534E variant in the Hyaluronan Binding Protein 
2 gene (HABP2, which encodes for a member of the 
peptidase S1 family of serine proteases) associated with 
familial NMTC. Based on the loss of function, the authors 
suggested that HABP2 is a tumor suppressor gene with 
dominant-negative effect [15]. Zhang and Xing reported 
the presence of this variant in heterozygous form in six 
individuals with PTC from four kindred [16]. Contrary to 
these reports, Tomsic et al. (2016) evaluated the variant 
HABP2 p.G534E in 179 individuals with family history of 
NMTC, 1160 sporadic PTC and 1395 controls showing an 
allele frequency of 0.61, 0.8 and 0.87, respectively. In six 
of eight families, the authors did not find co-segregation 
of the mutated allele and phenotype [17].
An intensive debate has been raised in literature [18-
20] based on the allele frequency described as common 
in several populations as well as in public and in house 
databases. In highly inbred Middle Eastern population, 
Alzahrani et al. (2016) described the absence of mutations 
in familial NMTC and only one of 509 sporadic cases 
harbored the variant [21]. In Hispanic individuals (281 
NMTC and 1105 population-matched controls) Bohórquez 
et al. (2016) reported that the HABP2 p.G534E was not 
significantly associated with cancer susceptibility [22]. In 
British population, no significant association was found 
between the p.G534E and NMTC [23]. Similarly, the 
variant was not associated with PTC neither in Spanish 
nor Australian families [24, 25]. According to Carvajal-
Carmona et al. (2016), the high allele frequency is a 
plausible explanation for the identification of carriers in 
different populations [26].
In this study we identified the HABP2 p.G534E 
mutation in three Brazilian families with history of PTC and 
BC. We also assessed the presence of the variant in sporadic 
PTC cases as well as in healthy Brazilian individuals. 
Extracellular matrix organization pathway and DNA repair 
function might be potentially deregulated and contribute to 
the risk of developing thyroid familial cancer.
RESULTS
Detection of HABP2 p.G534E variant in patients 
with familial history of NMTC and BC
Family 1
The male patient diagnosed with PTC (Case 1: IV-
2) was detected as homozygous for the HABP2 p.G534E 
variant by exome sequencing analysis and confirmed by 
Sanger sequencing. He had no clinical or pathological 
features of tumor aggressiveness (Figure 1, Supplementary 
Table 1). Seven family members (4 affected and 3 
unaffected) were screened by Sanger sequencing revealing 
six positive individuals for the HABP2 p.G534E (Figure 
1, Supplementary Table 1). The sister of the patient (IV-
1 with history of thyroid goiter and benign endometrial 
polyp) was homozygous for the mutation (Figure 1). The 
variant in heterozygous form was detected in his mother 
with skin carcinoma (III-5), the sister diagnosed with PTC 
(IV-5), two relatives with PTC (IV-5 and V-1) and two 
relatives unaffected by cancer (IV-3 and V-2) (Figure 1). 
His cousin diagnosed with BC (IV-6) was negative for 
p.G534E (Figure 1B).
Family 2
A woman with history of invasive ductal BC (Case 
2; III-12) presented the HABP2 p.G534E variant detected 
by WES. She was also diagnosed with four different benign 
tumors in a period of six years, including thyroid goiter, 
breast nodules, skin nodules and colorectal polyps. Sanger 
sequencing confirmed the presence of this variant in the 
index case and in two of three sisters (III-5: thyroid colloid 
goiter and colorectal hyperplasic polyp; III-6: thyroid 
follicular adenoma and benign breast nodule) (Figure 1A). 
The only sister diagnosed with PTC (III-9) was negative for 
p.G534E (Figure 1B, Supplementary Table 1).
Family 3
Sanger sequencing of HABP2 exon 13 was carried 
out in the index patient (Case 3) and three relatives 
from family 3. The 40 year-old female proband (III-5) 
diagnosed with PTC was negative for p.G534E mutation. 
Three relatives tested were positive for the same variant 
(Figure 1, Supplementary Table 1) including the mother 
(II-4: PTC), the female cousin (III-8: PTC) and the 
proband’s niece (IV-3: no history of cancer). The index 
patient had also breast cancer family history from maternal 
lineage (II-7) (Figure 1). Despite not being possible to 
assess her aunt (II-5), diagnosed with PTC and colorectal 
carcinoma, we may conclude she is positive for p.G534E 
since her daughter (III-9) carried this allele (Figure 1).
Sporadic PTC and healthy Brazilian individuals
The DNA of blood samples from both, 170 healthy 
individuals and 50 patients with sporadic PTC, were 
screened by Sanger sequencing to investigate the HABP2 
exon 13. Five healthy individuals were heterozygous for 
the variant, which represents an Allele Frequency (AF) 
of 0.0147. In PTC samples the AF was 0.04: two tumors 
were heterozygous and one was homozygous for p.G534E. 
Clinical features from sporadic PTC are presented in 
Supplementary Table 2.
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Variant prioritization and protein-protein 
interaction network
Our results suggested no co-segregation of the 
HABP2 p.G534E mutated allele and the phenotype. 
Furthermore, the frequency of this alteration in sporadic 
PTC and healthy Brazilian individuals indicated that this 
allele is common in Brazilian individuals. Based on these 
findings, the SRGAP1, PARP4 and SRRM2 candidate 
genes related to familial NMTC were also investigated. 
Although non-synonymous mutations have been found, 
none of them were identical to those previously reported.
Case 1 presented 14 variants (SRGAP1: p.L953V; 
SRRM2: p.P804T, p.R1934H; PARP4: p.I1564T, p.L1550P, 
p.S1459Y, p.S1394A, p.P1328T, p.G1280R, p.R1108C, 
p.L1080R, p.V1065A, p.M936T, p.A899T), three of them 
called deleterious in at least one bioinformatics prediction 
database for pathogenicity (dbNSFP, Supplementary 
Table 3). Two of them were classified as rare mutations 
according to 1000 Genomes [27] and 6500 Exomes [28]: 
SRGAP1 p.L953V (MAF 0.016) and SRRM2 p.R1934H 
(not described).
The index patient 2 showed 12 non-synonymous 
mutations (SRRM2: p.P804T; PARP4: p.I1564T, p.L1550P, 
p.S1459Y, p.S1394A, p.R1108C, p.L1080R, p.V1065A, 
p.M936T, p.S873N, p.I81V, p.A899T). Two of them, 
mapped in PARP4 gene, were predicted as pathogenic 
in at least one dbNSFP annotation: p.A899T (MAF: 
0.0323) and p.I81V (MAF: 0.6792). However, the p.I81V 
is considered common in populational public databases 
[27, 28].
To gain further insight into the function of other 
putative candidates associated with familial NMTC, we 
scrutinized WES data. Rare variants reported with MAF 
≤ 0.01 in 1000 Genomes phase 3 [27] and 6500 Exomes 
[28] were prioritized. Variants ranked per pathogenicity 
Figure 1: Segregation analysis and HABP2 p.G354 status in Family 1, 2 and 3. WT. Homozygous for the wild-type allele. 
GA. Heterozygous. AA. Homozygous for the p.G354E variant. Circles and squares represent female and male members, respectively. The 
probands are indicated by black arrows. Deceased members are represented by diagonal lines. (A) Eletroferograms representing HABP2 
mutation status for each tested individual. (B) Pedigree from families 1, 2 and 3.
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prediction, using dbNSFP, are described in details in 
Supplementary Table 4. A comprehensive pathway 
enrichment analysis using genes that harbor mutations 
predicted as deleterious in at least three dbNSFP was 
performed using KOBAS tool [29] and pathDIP 
[30]. Extracellular matrix organization pathway was 
significantly altered for case 1 (P=5.3x10-5; FDR=0.016). 
From higher to lower pathogenic degree, the mutated 
genes in this pathway included CTSB, TNXB, COL4A3, 
COL16A1, COL24A1, COL5A2, NID1, LOXL2, MMP11, 
TRIM24 and MUSK, (Figure 2A). Although not enriched 
in the same pathway, HABP2 was related to extracellular 
matrix degradation interacting with COL4A3. In addition, 
cancer related genes [31] as well as cytokines and 
growth factors, protein kinases, transcription factors and 
oncogenes presented pathogenic mutations. From these, 
MTA2, MYH11 and AMHR2 have highly pathogenic 
mutations displayed by pathogenic score (Figure 2A).
Similar analysis was performed for the altered genes 
found in the index Case 2. Although no significantly 
enriched pathway was deregulated, two tumor suppressor 
genes, MSH2 and NBN were mutated (Figure 2B). 
Although predicted as pathogenic, the p.G322D MSH2 
variant (c.965G>A) is classified as benign for the Lynch 
Syndrome phenotype (ClinVar Variation ID: 1762). 
Currently, the alteration c.596C>T; p.P199L in NBN gene 
has not been described in public databases. A considerable 
number of genes harboring pathogenic variants that codify 
protein kinases was detected including ERN2, MAP2K3, 
EPHA8, STK16, GRK7, MYLK, TTK, NEK1, ULK2, 
TRIM24 and TLK2. Alterations in cell differentiation 
markers, cytokines and growth factors, transcription 
factors and oncogenes were also detected (Figure 2B). 
The protein-protein interaction (PPI) network analysis 
using IID [32] revealed connections among FOXH1, 
LHX3, NBN, NEK1, STK16, which could be relevant in 
the phenotype (Figure 2B).
A comprehensive pathway enrichment analysis 
was performed using all proteins from Figure 2. 
The combination of the two cases identified their 
physical protein interactions using IID [32] (Figure 2; 
Supplementary Table 5). The resulting proteins were 
used to query pathDIP [30] that identified 31 significantly 
enriched pathways (p<0.043, FDR: BH-method; 
Supplementary Table 5), including leptin (p<0.0059), 
integrins (p<0.041), ECM-receptor interaction (p<0.036), 
EGFR and ERBB4 (p<0.043). Importantly, the most 
enriched terms in these pathways included focal-adhesion, 
EGF, Estrogen, PI3K, and prolactin (Supplementary 
Table 5).
DISCUSSION
Two probands with personal and or family history 
of BC and PTC evaluated by exome sequencing analysis 
presented HABP2 p.G534E variant. The probands and 
Figure 2: Protein-protein interaction (PPI) network analysis. PPI networks based on mutated genes detected by WES analysis, 
which were classified as deleterious in at least three dbNSFP pathogenicity predictions, and their interactions partners identified in IID and 
visualized with NAViGaTOR. Highlighted diamonds represent mutated genes classified according to MSigDB. Squares represent genes 
enriched for Extracellular Matrix Organization pathway. Pathogenic score and mutation is highlighted by spokes as per legend. (A) Mutated 
genes identified in the proband 1. (B) Mutated genes identified in the index patient 2.
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several relatives from these two families diagnosed with 
PTC, thyroid goiter, thyroid nodules, BC and other tumors 
were tested using Sanger sequencing method. Our data 
revealed the absence of complete co-segregation between 
the mutation and the phenotype. Two individuals from 
Family 1, including one diagnosed with PTC and his 
healthy sister, harbored homozygous p.G534E mutation as 
result of consanguineous marriage. The homozygous cases 
have no clinical or pathological differences compared with 
heterozygous cases. The third family evaluated only by 
Sanger sequencing revealed three of four individuals with 
the p.G534E variant; however, the index patient who had 
PTC was negative for the mutation. Furthermore, two 
healthy individuals from families 1 and 3 (both, IV-3) 
were positive for the mutation. Overall, these findings 
give additional support to the absence of the association 
between NMTC and HABP2 p.G534E variant.
Interestingly, we have identified patients diagnosed 
with BC positive for the HABP2 p.G534E mutation, which 
is additional evidence that this variant is not associated 
with thyroid disease. To our knowledge, breast cancer has 
not been described as associated with p.G534E mutation.
To investigate the HABP2 p.G534E allele frequency 
in Brazilian population, 170 healthy individuals were 
evaluated and five of them were heterozygous for the 
mutation (AF = 0.0147). The ethnicity of Brazilian 
individuals is questionable mostly by the high level of 
miscegenation; however, the Brazilian genetic background 
also derives from the European population [33, 34]. 
According to the last update of 1000 Genomes project 
Phase 3 [27] and considering European allele frequency, 
the minor allele frequency of p.G534E is 0.027, which is 
not significantly different from the Brazilian individuals 
tested in our study (Fisher’s exact test, P = 0.3). Similarly, 
no significant results were found in the comparison 
with the European allele frequency in ExAC database 
(unfinished) [35], in which p.G534E allele frequency is 
0.033 (Fisher’s exact test, P = 0.065).
The HABP2 mutation allele frequency was 0.04 in 
50 sporadic PTC samples, which is consistent with data 
reported by TCGA (0.047). The comparison between 
healthy Brazilian individuals and sporadic PTC cases 
revealed no significant difference (Fisher’s exact test, P = 
0.124). Based on these findings, Brazilian allele frequency 
is concordant with public databases and no association of 
p.G534E with sporadic PTC was found.
Since Gara et al. (2015) reported the HABP2 
p.G534E as a candidate to hereditary NMTC [15], 
several studies have been reported aiming to establish 
the involvement of this mutation as a non random event 
in different populations. Except for Zhang et al. (2016) 
[16], these studies have failed to prove the association 
between NMTC and HABP2 variant, including our study. 
Data reported in Spanish population [22, 24], highly 
inbred Saudi Arabian population [21], United Kingdom 
and Ireland [23], as well as patients followed by Ohio 
State University, United States [17], have demonstrated 
no involvement of p.G534E as a predisposition gene in 
thyroid tumors.
In the past few years, new variants associated 
with familial NMTC have been reported including 
SRGAP1 (Q149H and R617C), SRRM2 (p.S346F) and 
PARP4 (p.G496V and p.T1170I) [12-14]. These specific 
variants were not detected in our probands (cases 1 
and 2). However, the rare mutation SRRM2 p.R1934H 
(pathogenic in four pathogenicity predictions and no 
described in dbSNP so far) was detected in the index 
Case 1 (Supplementary Table 3). Interestingly, the allele 
frequency of this variant was 2.594x10-4 and 2.999x10-5 
in Latino and European populations (ExAC project, not 
finished) [35], respectively. Further studies are necessary 
to better evaluate the involvement of the SRRM2 in 
familial NMTC.
A considerable number of alterations with potential 
to modify the effect of tumor suppressor genes have been 
described [36]. In addition, the combination of different 
mutations in cancer predisposition genes has implicated 
in phenotype overlapping and a synergic interaction, 
where several loci may contribute with the phenotype 
[37]. For instance, a combination of papillary thyroid 
carcinoma and paraganglioma in the same patient revealed 
alterations in PTEN and SDHC genes, leading to Cowden 
syndrome and pheochromocytoma–paraganglioma 
diagnosis [38]. A recent study suggested that the mutation 
background of an individual might modulate the severity 
of the Mendelian diseases [39]. In our study, no classical 
mutations associated with hereditary cancer syndromes 
were identified, however several rare and predicted as 
pathogenic mutations were detected in the Cases 1 and 
2. For instance, Case 1 harbors pathogenic mutations 
in genes involved in extracellular matrix organization 
pathway, similar with HABP2 protein function [40]. The 
extracellular matrix proteins are involved in angiogenesis, 
cell growth, fibrosis, cell signaling and disrupting of tissue 
morphogenesis [41]. In thyroid cancer, dysfunction of 
COLL1 and LOX genes, promoted by BRAF and PTEN 
knockdown, were associated with ripping stiffen of Col1 
matrix, enhancing cell motility and tumor progression 
[42]. In our analysis, CTSB gene harbors a mutation 
predicted as highly pathogenic (Figure 2A). Protein 
encoded by CTSB regulates negatively Wnt/β-catenin 
signaling pathway [43] related with tumor development 
[44]. Extracellular matrix is essential for breast normal 
function (as mammary gland remodeling before and 
after lactation) and tumor development, progression and 
metastasis, as its composition differs between metastatic 
and non-metastatic breast tumor stages [45]. Inhibitors 
of extracellular components as well as integrins, 
proteoglycans, metalloproteinase, collagens and C1-
peptidase protein families have demonstrated promising 
pre-clinical results in breast cancer [45]. For instance, 
cathepsin B (CTSB gene, reported as mutated in our study) 
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inhibition has been reported as associated with reduced 
bone metastasis in breast cancer from mice [46].
Although predicted pathogenic alterations were 
found involving MSH2 and NBN, no significantly enriched 
pathway was found for index Case 2. MSH2 p.G322D 
variant is described as benign in the Lynch Syndrome 
diagnosis (ClinVar Variation ID: 1762) [47]. Recently, the 
MSH2 p.G322D variant was associated with breast cancer 
risk in Polish women [48]. NBN is DNA repair family 
gene, involved in the MRE11/RAD50/NBN complex, with 
nine variants (rs1805794, rs1805790, rs36226237, rs924, 
rs376639, rs1061302, rs1063054, rs2735383, rs805794) 
described as associated with high cancer risk [49]. 
Recently, Kraus et al. investigate the mutational status 
of 581 BC patients using a panel-based screening of 14 
breast and ovary susceptibility genes, including NBN. One 
patient presented a deleterious variant c.657_661del5 of 
NBN [50]. In addition, the c.657del5 variant in the NBN 
gene was reported as associated with pancreatic cancer 
predisposition [51]. Differently of these reports, we found 
the variant c.596C>T p.P199L in our case 2. Eleven 
mutated genes classified as protein kinases were also 
identified in our Case 2 (Figure 2B). Interestingly, a group 
of proteins highly connected and with the same function 
might lead to cellular dysfunction and pre-cancer stages. 
In our study, the index patient 2 was diagnosed with BC, 
benign breast nodule, thyroid nodules and colorectal 
polyps. The presence of mutations in MSH2 and NBN has 
the potential to increase the risk of the patient developing 
multiple primary tumors.
A comprehensive pathway enrichment analysis 
using pathDIP and proteins from the network (Figure 2) 
revealed 31 significantly enriched pathways (p<0.043), 
including leptin, integrins, interleukins, ECM-receptor 
interaction, EGFR and ERBB4. Interestingly, the most 
enriched terms in the titles of these pathways included 
focal-adhesion, EGF, Estrogen, PI3K, and prolactin 
(Supplementary Table 5). In the current study, we focused 
on comprehensive pathway enrichment analysis. In 
the future, using additional patient cases and larger PPI 
network, we could use additional tools that combine 
mutation data (such as HotNet [52]) or arbitrary omics 
data (e.g., KeyPathwayMiner [53], NBS [54], MUFFIN 
[55], VarWalker [56]) with signaling networks.
In conclusion, no co-segregation of the HABP2 
p.G534E was found in three families with NMTC and 
breast cancer. The variant is not significantly associated 
with PTC in Brazilian population and showed similar 
allele frequency in tumor samples and healthy individuals. 
Our data also refute the dominant negative effect of this 
variant as proposed by Gara et al. (2015) [15]. Alterations 
reported here may contribute to high risk of NMTC. A 
limitation of our study was the impossibility to evaluate 
the exome of all affected family members, compromising 
the identification of other putative locus of predisposition 
that segregate with the phenotype. Our results point out 
that the HABP2 p.G534E mutation is not associated with 
hereditary NMTC. Genetic mechanisms involved in 
familial NMTC remain elusive and further investigation 
is necessary.
MATERIALS AND METHODS
Ethics statement
The use of the clinical samples was approved by 
the Institutional Human Research Ethics Committees at 
A.C. Camargo Cancer Center, Sao Paulo and Faculty of 
Medicine, UNESP, Botucatu, Sao Paulo, Brazil (FMB-
PC-197/2012; CEP1175/08ext). Informed consent was 
obtained from all patients, and the experiments were 
performed in accordance with relevant guidelines and 
regulations.
Patients and clinical samples
Twenty index cases with personal and family history 
of NMTC, thyroid disease as well as breast carcinoma 
were evaluated by whole exome sequencing. We focused 
this study on two patients that presented HABP2 p.G534E 
variant, one diagnosed with invasive ductal breast 
carcinoma and the other with PTC. Family members from 
index patient 1 (7 relatives) and 2 (three relatives) were 
included in this study. Although these patients presented 
tumors frequently described in the Cowden Syndrome 
(CS) spectrum, none of them fulfilled the clinical criteria 
for CS. In addition, the index patients were negative for 
pathogenic mutations in PTEN, BRAC1, BRCA2 and TP53 
genes. A third index patient diagnosed with PTC, with 
family cancer history of PTC and BC and three relatives, 
were also investigated for HABP2 status using Sanger 
sequencing. All patients were prospectively followed by 
the Department of Oncogenetics, A.C. Camargo Cancer 
Center, Sao Paulo, Brazil. Clinical features and family 
history of all individuals are presented on Supplementary 
Table 1.
Index Case 1was diagnosed with PTC at 41-years-
old. His familial history included a nephew diagnosed 
with PTC (27 years old), an aunt diagnosed with BC 
(90 years old) and skin carcinoma (87 years old) who 
had three daughters, one diagnosed with PTC (55 years 
old), and two with BC (at age 60 and 61, respectively) 
(Figure 1B, Supplementary Table 1). The proband’s 
mother developed a skin tumor (75 years old) and 
thyroid colloid goiter (67 years old). She was married 
with a first-degree cousin.
Index Case 2 presented a BC (46 years old) and a 
history of several benign lesions (benign nodules from 
breast, skin, thyroid and colorectal polyp). Her sisters 
presented history of cancer: one with papillary thyroid 
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carcinoma (66 years old) and the other with BC (58 
years old). Her niece was diagnosed with breast and 
ovary carcinomas (47 years-old); two aunts with BC, 
beyond other malignancies in the family (Figure 1B).
The proband from the third family was diagnosed 
with PTC (40 years old) concurrent with breast benign 
nodules. Her family history encompasses a mother with 
PTC (40 years old), a female cousin with PTC (38 years 
old), an aunt with colorectal cancer (40 years old) and 
PTC (50 years old), and a second-degree female cousin 
diagnosed with BC (50 years old). This family also 
presented individuals with throat, pleura and other tumors 
types in the maternal lineage (Figure 1B, Supplementary 
Table 1).
A cohort of 170 healthy individuals (84 males 
and 86 females) was recruited at the same hospital and 
screened for the variant p.G534E. These individuals 
were cancer-free so far, with no known thyroid diseases 
or family history of cancer. The median age of this set 
of cases was 49 years (range 21-87 years old). Fifty 
sporadic PTC (11 male and 39 female) with median age 
of 40 years (range 21-75 years old) were also assessed. 
These patients have no family history of cancer. Clinical 
and histological characteristics of the sporadic PTC are 
detailed in Supplementary Table 2.
Genomic DNA extraction
Genomic DNA was extracted from blood leukocytes 
using Qiacube DNA Blood kit (Qiagen, Valencia, CA) for 
two index patients and all healthy individuals. Family 
members from HABP2 p.G534E positive patients, as well 
as the individuals for family 3, had their DNA extracted 
from saliva using Oragene-DNA (DNA Genotek, Ottawa, 
CA). Gentra Puregene Tissue Kit (Qiagen, Valencia, CA) 
was used to obtain DNA from fresh frozen PTC tissue 
samples. The DNA extraction followed the manufacturer’s 
recommendations.
Whole exome sequencing (WES) analysis
Whole exome libraries were prepared with Exome 
Nextera Enrichment kit-Illumina (San Diego, California, 
USA) with 62 Mb target regions. Paired-end sequencing of 
100 bp was carried out in HiSeq2500 Illumina (San Diego, 
California, USA), at the Center for Functional Genomics 
core facility, ESALQ-University of Sao Paulo, Piracicaba, 
Brazil.
Raw reads data were trimmed with Seqyclean 
software [57]. Paired-end reads were aligned to UCSC 
hg19 using Botiwe2 [58], in local-alignment mode. WES 
analysis achieved coverage of 53x. Duplicate reads were 
marked using the MarkDuplicates utility from Picard [59] 
to filter out PCR artifacts. Variants were detected with 
GATK [60] and SAMtools [61]. ANNOVAR [62] was 
used for data annotation.
Exonic alterations were prioritized according to 
their function focusing on frameshift, splice-site and 
non-synonymous variants. Data were compared with 
1000 Genomes phase 3 [27] and 6500 Exomes [28] and 
variants reported with an allele frequency ≤0.01 were 
selected. After the annotation with dbNSFP database 
[63], the alterations classified as deleterious in at least 
three pathogenicity predictions were selected to perform 
pathway enrichment and network analysis. Pathways 
enrichment analysis was performed using KOBAS 2.0 
tool [29]. Selected variants were then used to identify 
biological context by querying protein-protein interaction 
(PPI) database Interologous Interaction Database v. 
2016-03 [32] (http://ophid.utoronto.ca/iid). The resulting 
network was visualized in NAViGaTOR v3 [64] (http://
ophid.utoronto.ca/navigator).
To elucidate biological functions of the protein 
network (Figure 2), we performed a comprehensive 
pathway enrichment analysis. The Pathway Data 
Integration Portal (pathDIP) was used to perform 
enrichment analysis across pathways from 20 major 
pathway databases (pathDIP ver. 2.5; [30]). We considered 
literature curated gene: pathway memberships and those 
predicted according to experimentally detected protein-
protein interactions (including interactions experimentally 
detected between orthologues plus FpClass [65] 
interactions with minimum confidence level for predicted 
associations equal 0.95 (for more details see pathDIP 
documentation in http://ophid.utoronto.ca/pathDIP).
Data confirmation and validation
The presence of the variant p.G534E detected 
by WES was confirmed by Sanger re-sequencing in the 
two index cases, their family members and in the family 
3 members. For the HABP2 exon 13 amplification the 
following primers were constructed: forward primer 
3’-CCCTGACACCCCCTGGAGAG-5’; and reverse 
primer 3’-GCTCTGGAGGTGTCCATTGT-5’ (Gara et al., 
2015). Polymerase chain reaction was performed according 
to standard protocols using Platinum Taq DNA Polymerase 
(Life Technologies, Carlsbad, California, USA) with the 
following conditions: 2 min at 94ºC; followed by 35 
cycles of 45 sec at 94ºC, 30 sec at 63ºC and 45sec at 72ºC; 
followed by 10 min at 72ºC for final extension. Sanger 
sequencing was carried out using BigDye terminator v3.1 
and ABI Prism 3130XL sequencer, both from Applied 
Biosystem (Foster City, California, USA).
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